Yonsei University Health System

Digital Twin Technology Predicts Amiodarone Effectiveness in Atrial Fibrillation Patients

7 months ago

• A digital twin of the left atrium, created by merging CT images with electroanatomical mapping data, can simulate the effects of amiodarone (AMD) on atrial fibrillation (AF). • The digital twin accurately predicted the effectiveness of amiodarone in maintaining sinus rhythm in patients post-AF ablation, identifying those likely to benefit from the drug. • Virtual amiodarone tests using the digital twin platform showed dose-dependent electrophysiological changes, offering insights into optimal drug concentrations. • This technology may help personalize treatment strategies for atrial fibrillation, reducing recurrence rates and improving patient outcomes.

Zanidatamab Plus Chemotherapy Shows Promise in HER2+ Metastatic Colorectal Cancer

8 months ago

• Zanidatamab with mFOLFOX6-2, with or without bevacizumab, demonstrated significant antitumor activity in first-line HER2-positive metastatic colorectal cancer (mCRC). • The confirmed overall response rate (cORR) reached 90.9% across both treatment arms, with a 100% disease control rate, indicating substantial clinical benefit. • The combination therapy presented a manageable safety profile, with no treatment-related deaths and no discontinuations due to treatment-related adverse events (TRAEs). • These findings support zanidatamab-based combinations as a potential first-line treatment option for patients with HER2-positive mCRC.

Phase 3 CLEAR Study Shows Improved Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Renal Cell Carcinoma

2 years ago

The phase 3 CLEAR study demonstrates that lenvatinib combined with pembrolizumab significantly improves efficacy outcomes over sunitinib in patients with advanced renal cell carcinoma (RCC), regardless of baseline prognostic features such as metastases location, prior nephrectomy, and sarcomatoid histology.